Abstract:Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the recent work of Boursier et al., who investigated the relationship between gut dysbiosis and the severity of nonalcoholic fatty liver disease (NAFLD).1 With a well‐characterized and well‐balanced population of biopsy‐proven NAFLD patients, the diversity and composition of gut microbiota were investigated using the MiSeq sequencing platform. Several key functional bacterial phylotypes such as Bacteroides, Prevotella, and Ruminococcus were identified to be associated with the severity of NAFLD. Besides the classical predictors, the present data indicated that the gut microbiota would provide new insights on the diagnosis of NAFLD. For gut microbiomic analysis, both the diversity indices and taxonomic composition were used to define the status of the gut ecosystem. Only alterations of the taxonomic composition, especially those abundant genera, could not determine the status of the gut ecosystem as dysbiosis accurately. Other indices such as α‐diversity, β‐diversity, and Good's coverage would provide more meaningful information for the alterations of the overall structure and composition of gut microbiota. However, the important indices of diversity, such as Shannon and Simpson, seemed to be ignored in the Boursier et al. study as they could stress considerable variation in response to changes in the richness and evenness of the gut microbiota.2 In addition, the Firmicutes/Bacteroidetes ratio was considered to be representative of health status and might be considered an important marker to evaluate eubiosis or dysbiosis of the gut. Without healthy control, the diagnosis of gut dysbiosis might be arbitrary in these patients with NAFLD. For microbiomic biomarker discovery and explanation, the alterations of gut microbiota also could be analyzed by linear discriminant analysis effect size, which would emphasize both statistical significance and biological relevance. Linear discriminant analysis effect size could identify not only the differences of abundant bacteria but also those nonabundant ones. As one of the microbiota‐driven diseases, NAFLD could not just alter those abundant bacteria.4 In addition, the sensitivity and specificity of the microbiota‐targeted biomarkers should be provided in order to facilitate the clinical application for NAFLD noninvasive discrimination. Receiver‐operating characteristic curves could be used to identify the best cutoff levels for these bacteria, while the respective areas under the curve could represent the diagnostic accuracy for NAFLD. With larger scales of NAFLD patients in different stages, the diagnostic value of these genera with best cutoff levels could be verified. Furthermore, the endotoxin‐induced inflammation was not correlated with those altered genera, which would clarify their relationships in the microbiota‐gut‐liver axis. In conclusion, the study provided new insights; however, the microbiota evaluation and the diagnostic accuracy were still limited. Without a comprehensive understanding of the overall structure and composition of the gut microbiota and the diagnostic value of the key functional bacteria, it was difficult to decipher the real roles of the gut microbiota in the development of NAFLD.

The Determination of Endotoxin, Ieptin, IL-6 and IL-8 in Patients with Nonalcoholic Fatty Liver Disease

Study on the Relationship Between Different Patterns of Nonalcoholic Fatty Liver Disease and the Levels of TNF-α and IL-6

Association Between Serum Free Fatty Acid Levels and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study

Serum Fetuin A Level is Associated with Nonalcoholic Fatty Liver Disease in Chinese Population

Association Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease

ASSA13-10-11 Nonalcoholic Fatty Liver Disease is Associated with Subclinical Atherosclerosis

Study on the Relationship between Phospholipids and Nonalcoholic Fatty Liver Disease

Serum Fetuin B Level Increased in Subjects of Nonalcoholic Fatty Liver Disease: a Case-Control Study.

Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-Alcoholic Fatty Liver Disease

Predictive Roles of Gut Dysbiosis on the Severity of Nonalcoholic Fatty Liver Disease

Serum Proteomic Analysis Revealed Diagnostic Value of Hemoglobin for Nonalcoholic Fatty Liver Disease

Insulin Resistance in Connection with the Serum Level of Leptin and Adiponectin in Nonalcoholic Fatty Liver Disease

Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels.

Association of the Frequency of Peripheral Natural Killer T Cells with Nonalcoholic Fatty Liver Disease

The Role of Intestinal Microbiota, Endotoxemia and Systemic Inflammation in the Pathogenesis of Nonalcoholic Fatty Liver Disease

The variation of system immune and intestinal immune in non-alcoholic fatty liver disease in rats

Relationship Between Leptin Resistance and Nonalcoholic Fatty Liver in Male Patients

Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease

Relevance of combined influence of nutritional and inflammatory status on non‐alcoholic fatty liver disease and advanced fibrosis: A mediation analysis of lipid biomarkers

A198 RELATIONSHIP BETWEEN HEPATIC GENE EXPRESSION AND MICROBIOME ACCORDING TO DISEASE SEVERITY IN OBESE PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Bioinformatic Analysis of Key Biomarkers and Infiltrating Immune Cells in Nonalcoholic Fatty Liver Disease.